During the past decade, considerable progress has been made toward integrating patient perspectives and input into biomedical research, as evidenced by the proliferation of legislation, regulatory guidance, and resources aimed at expanding patient-centric approaches. Among device and digital health developers, however, uptake of means to integrate patient input varies widely across product types and companies. Some biopharmaceutical companies are beginning to quantify the value and likely ROI of patient engagement, but little is known about how medical device and digital health companies evaluate patient engagement across the R&D process in their decision-making processes. This session will explore the factors that contribute to the value of engaging patients for these stakeholder groups and the metrics used to capture value and ROI across device and digital health companies and their partners. 

Moderator

Kristin Schneeman

Senior Director, FasterCures, Milken Institute

Speakers

Kathryn Capanna

Acting Associate Director, Office of Strategic Partnerships and Tech Innovation, Centers for Devices and Radiological Health, US Food and Drug Administration

Andrew Fish

President and CEO, Medical Device Innovation Consortium

Ben Lenail

Commercial Advisor, CIONIC

Ivana Stojanovic

Vice President, Market Access and Direct to Consumer Marketing, CVRx

Chris Wasden

Chief Strategy Officer, Twill